Idera Pharma (IDRA) Regains IMO-2055 Rights

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany. During the collaboration, Merck KGaA conducted Phase 1 trials of IMO-2055 in several cancer indications and has an ongoing randomized Phase 2 trial of IMO-2055 in combination with Erbitux® in patients with squamous cell cancer of the head and neck (SCCHN). As previously announced in July 2011, Merck had informed Idera that it would not continue clinical development of IMO-2055 beyond completing the ongoing Phase 2 trial in SCCHN.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Real and RE/MAX Holdings receive court approval for merger
• Gray Media closes $750M note offering to refinance higher-rate debt
• Nuvectis Pharma (NVCT) files $200M mixed shelf